Bortezomib
![]() | |||
![]() | |||
(IUPAC) ime | |||
---|---|---|---|
[(1R)-3-metil-1-[(2S)-3-fenil-2-(pirazin-2-ilformamido)propanamido]butil]boronska kiselina | |||
Klinički podaci | |||
AHFS/Drugs.com | Monografija | ||
Identifikatori | |||
CAS broj | 179324-69-7 | ||
ATC kod | L01XX32 | ||
DrugBank | DB00188 | ||
ChEMBL[1] | CHEMBL52717 ![]() | ||
Hemijski podaci | |||
Formula | C19H25BN4O4 | ||
Mol. masa | 384.237 | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | |||
Način primene | Intravenozno |
Bortezomib (originalno PS-341) je bio prvi terapeutski inihbitor proteazoma koji je testiran na ljudima. FDA je odobrila ovaj lek za tretman relapsirajuće mijelomne bolest i limfoma mantl ćelija.[2][3][4][5][6][7]
Reference
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-11. PMID 15199612
- ↑ Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007 Apr;21(4):838-42. Epub 2007 Feb 1. PMID 17268529
- ↑ Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. PMID 14695130
- ↑ Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. PMID 15953001
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
- ↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.
Spoljašnje veze
![]() | Portal Medicina |
![]() | Portal Hemija |
![](http://upload.wikimedia.org/wikipedia/commons/thumb/4/4a/Commons-logo.svg/15px-Commons-logo.svg.png)
Bortezomib na Wikimedijinoj ostavi
- Bortezomib